Tolcapone - Corino Therapeutics/SOM Biotech

Drug Profile

Tolcapone - Corino Therapeutics/SOM Biotech

Alternative Names: Amyloid inhibitor - SOM Biotech; CRX-1008; SOM 0226

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SOM Biotech
  • Developer SOM Biotech; Vall d-Hebron Research Institute
  • Class Antiparkinsonians; Benzophenones; Nitrophenols; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • New Molecular Entity No
  • Available For Licensing Yes - Amyloid polyneuropathy

Highest Development Phases

  • Phase II Amyloid polyneuropathy

Most Recent Events

  • 22 May 2017 Tolcapone licensed to Corino Therapeutics worldwide
  • 31 Mar 2017 Phase-II development for Amyloid polyneuropathy is ongoing in Spain (PO)
  • 31 Mar 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top